
Kies je etiket
direct zichtbaar op de vialSurvodutide
GLP-1
- Verzonden vanuit Duitsland
Bestelling
- DHL met tracking
- Discrete verpakking
4.6 van 5 op Trustpilot73 reviews
Ook gezocht als: Survodutid · BI 456906
In één oogopslag
Survodutide in cijfers
De kerncijfers uit ons lexicon.
Volledig lexiconartikel- Class
- GLP-1 / glucagon dual agonist
- Half-life
- Several daysweekly dose
- Frequency
- Once weeklysubcutaneous
- Form
- Lyophilised powderreconstituted with BAC water
- Sizes
- 10 mg1 size in the shop
What studies show
All 5 sources in the lexicon- up to~15 %le Roux et al., Lancet Diabetes & Endocrinology, 2024
Phase 2 study in MASH and liver fibrosis (opens in a new tab)
Sanyal et al., New England Journal of Medicine, 2024Phase 3 trial SYNCHRONIZE-1 in obesity without diabetes (725 adults, 76 weeks) (opens in a new tab)
le Roux et al., New England Journal of Medicine, 2026
Er is nog geen labanalyse voor Survodutide. Stem eropLaat het zelf testen, wij betalen de helftAlle labanalyses
Kennis
Alles over Survodutide
Uitgebreide informatie volgt binnenkort.
Dosering
Doseringsinformatie laden …
Handig om erbij te hebben
Wat je erbij nodig hebt
Bacteriostatisch water wordt automatisch aan je winkelwagen toegevoegd. Spuiten en doekjes met één klik.
Insulinespuiten
10 stuks · 5.50 €
Alcoholdoekjes
50 stuks · 10 €
Hoeveel water?
Eenheden op de spuit voor jouw vialgrootte.
Naar de calculator →Is Survodutide approved?
No. ChEMBL lists Survodutide with phase 3 as the highest phase. The first phase 3 trials (SYNCHRONIZE-1, SYNCHRONIZE-2 and SYNCHRONIZE-MASLD) are finished and were published in 2026, others are still running. The information here describes the state of research and is not a recommendation for use.
How does Survodutide differ from Semaglutide and Retatrutide?
The receptors. Semaglutide acts only on the GLP-1 receptor, Survodutide also on the glucagon receptor, Retatrutide additionally on GIP. The glucagon part acts mainly in the liver, which is why Survodutide is also tested in fatty liver. In a phase 2 trial in type 2 diabetes the higher levels lowered weight more than semaglutide after 16 weeks.
What did the phase 3 trials show?
In SYNCHRONIZE-1 (without diabetes) weight fell by 12.2 and 13.0 percent after 76 weeks, by 5.4 percent on placebo. In SYNCHRONIZE-2 (with type 2 diabetes) it was 8.2 and 9.8 versus 3.9 percent, HbA1c fell by 0.9 and 0.8 percentage points. In SYNCHRONIZE-MASLD liver fat fell by at least 30 percent in 68.5 percent, on placebo in 28.6 percent.
What is known about the liver?
In a phase 2 trial with biopsy MASH improved without worsening of fibrosis in 43 to 62 percent depending on the dose, in 14 percent on placebo. Fibrosis improved in 34 to 36 versus 22 percent. A study in liver cirrhosis tested uptake and tolerability. Two large phase 3 trials on MASH are still running.
How high were the doses in trials?
The highest study dose was 6 mg per week, in the liver trial and the phase 3 programme. All trials raise the dose in steps over weeks. In the phase 2 trial in overweight the effect rose only a little from the second level on. The entry describes the same principle: start low and only increase until an effect is noticeable. This is not a dosing recommendation.
Which side effects were seen?
Mainly gastrointestinal effects, mostly mild to moderate. In SYNCHRONIZE-1 80.9 and 89.7 percent had them, 47.9 percent on placebo. In the liver trial nausea, diarrhoea and vomiting were clearly more common with Survodutide than with placebo. The trials describe the complaints mainly during escalation.
Which trials are still running?
Three of the listed phase 3 trials are still recruiting: LIVERAGE on MASH with fibrosis (planned end 2031), LIVERAGE-Cirrhosis on MASH with cirrhosis and a trial on blood sugar in type 2 diabetes. The large cardiovascular safety trial with 5,531 participants is finished, results had not been published by October 2026.
Gerelateerd
Gerelateerde producten
Tirzepatide
Peptiden · GLP-1 & vetverlies GLP-1 & vetverlies
10 maten
Laboratoriumgetest
= vanaf 10 €/vial
Retatrutide
Peptiden · GLP-1 & vetverlies GLP-1 & vetverlies
11 maten
Laboratoriumgetest
= vanaf 16 €/vial
Semaglutide
Peptiden · GLP-1 & vetverlies GLP-1 & vetverlies
6 maten
Laboratoriumgetest
= vanaf 10 €/vial
Mazdutide
Peptiden · GLP-1 & vetverlies GLP-1 & vetverlies
2 maten
= vanaf 32 €/vial
Survodutide